Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. August 2020 08:30 ET | Quelle: Celsion CORP

Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study for Overall Survival

Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue Cohort of 26 Consecutive Patient Deaths Differs Substantially from Predicted Behavior and from the Balance of the...
04. November 2019 08:00 ET | Quelle: Celsion CORP

Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

The Data Monitoring Committee Signals that Patient Safety Data and Data Quality Meets Expectations and Company is to Proceed to Next Interim Analysis.The Pooled Progression-Free Survival (PFS) Data is...
18. Dezember 2018 08:00 ET | Quelle: Celsion CORP

Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® for Treatment of Primary Liver Cancer

Current Combined, Blinded Progression-Free Survival (PFS) Rate for Both Treatment Arms Reaches 21.2 Months Compared to 19.8 Months for the Intent-To-Treat (ITT) Population in the HEAT Study Post-Hoc...